Crouch Dennis J, Walsh J Michael, Cangianelli Leo, Quintela Oscar
Research and Development, Ameritox, LTD, Midland, TX 79705, USA.
Ther Drug Monit. 2008 Apr;30(2):188-95. doi: 10.1097/FTD.0b013e3181679249.
This study was a part of a collaborative U.S./E.U. international research effort (Roadside Testing Assessment, ROSITA II) to assess illegal drug use among motor vehicle operators suspected of driving while under the influence of drugs and to evaluate the effectiveness of point-of-collection oral fluid drug detection technologies. A goal of the study was to assess commercial oral fluid drug testing devices for potential use in law enforcement. Ten devices were evaluated in the laboratory for their ability to meet manufacturers' claimed (and proposed) cutoff concentrations for the detection of amphetamine(s), cocaine/metabolite, opiates, cannabinoids, and benzodiazepines (2 devices). The field study portion of the research was conducted in major cities in the United States and Western Europe by teams of scientists working in collaboration with the local police. In Salt Lake City, Utah, the Drugwipe, Securetec, Ottobrunn, Germany (Securetec) oral fluids drug testing device was also evaluated in the field by testing suspected drug-impaired drivers. During the initial phase of the field study, 40 subjects were recruited. Drugwipe results were compared with laboratory-based immunoassay and mass spectrometry results and demonstrated that calculated sensitivities were between 75% and 100% depending on drug class. Specificities varied from 36% for cannabinoids to over 95% for opiates. During the second phase of the field study, 267 subjects were recruited. The Drugwipe sensitivities were 36.4%, 35.9%, 42.9%, and 7.7%, respectively, for amphetamine(s), cocaine, opiates, and cannabinoids. The Drugwipe specificities were 99.2%, 97.4%, 99.6%, and 99.6%, respectively, for amphetamine(s), cocaine, opiates, and cannabinoids. Drugwipe failed to meet the study criteria for acceptable device performance, required performance sensitivities, and specificities 90% or greater.
本研究是美国/欧盟国际合作研究项目(路边测试评估,ROSITA II)的一部分,旨在评估涉嫌在药物影响下驾驶的机动车驾驶员的非法药物使用情况,并评估收集点口腔液药物检测技术的有效性。该研究的一个目标是评估商业口腔液药物检测设备在执法中的潜在用途。在实验室中对10种设备进行了评估,以确定它们是否能够达到制造商声称的(以及提议的)检测苯丙胺、可卡因/代谢物、阿片类药物、大麻素和苯二氮卓类药物(2种设备)的截断浓度。研究的实地调查部分由与当地警方合作的科学家团队在美国和西欧的主要城市进行。在犹他州盐湖城,还通过对涉嫌药物影响驾驶的司机进行测试,在实地对德国奥托布伦的Drugwipe、Securetec口腔液药物检测设备进行了评估。在实地研究的初始阶段,招募了40名受试者。将Drugwipe的结果与基于实验室的免疫分析和质谱结果进行了比较,结果表明,根据药物类别,计算出的灵敏度在75%至 100% 之间。特异性从大麻素的36%到阿片类药物的超过95%不等。在实地研究的第二阶段,招募了267名受试者。Drugwipe对苯丙胺、可卡因、阿片类药物和大麻素的灵敏度分别为36.4%、35.9%、42.9%和7.7%。Drugwipe对苯丙胺、可卡因、阿片类药物和大麻素的特异性分别为99.2%、97.4%、99.6%和99.6%。Drugwipe未能达到研究设定的可接受设备性能、所需性能灵敏度和90%或更高特异性的标准。